Europe's First Aldosterone Blocker, West Nile Nearing Cyprus, and Depression Gone in Three Days

Three regulatory and clinical milestones reshaped European medicine this Monday — joined by a surveillance alert that brings a familiar summer hazard closer to Cyprus's doorstep.

Monday, 17 August: Europe Approves a New Class of Blood-Pressure Drug

The European Medicines Agency has approved baxdrostat (brand name Nilemdo) for adults with treatment-resistant hypertension — the first drug in the aldosterone synthase inhibitor class to reach the European market. Aldosterone is a hormone produced by the adrenal glands that raises blood pressure by causing the kidneys to retain sodium; baxdrostat blocks the enzyme that synthesises it, reducing aldosterone levels selectively without suppressing the related hormone cortisol.

The approval rests on the HALO Phase 3 programme, in which 712 patients whose blood pressure remained above target on three or more medications saw systolic pressure fall by an average of 11.4 mmHg more than placebo after 12 weeks — a clinically meaningful difference. The drug is taken as a single daily tablet.

Treatment-resistant hypertension — conventionally defined as blood pressure above 130/80 mmHg despite three guideline-directed medications including a diuretic — affects an estimated 10–15% of the roughly 150 million Europeans living with high blood pressure. Existing add-on options such as spironolactone work for some patients but can trigger hormonal side effects that limit tolerability, including breast tissue changes and sexual dysfunction. Baxdrostat's selectivity for aldosterone synthase may reduce those side effects, though longer post-marketing studies will be required to confirm this in routine clinical use. The EMA's approval covers all 31 European Economic Area countries; the UK's MHRA and the US FDA are reviewing separate applications.

Monday, 17 August: West Nile Virus Accelerating Across the Mediterranean

The European Centre for Disease Prevention and Control reports 143 confirmed cases of West Nile neurological disease — the severe, potentially fatal form of the infection — across Greece, Italy, Romania, and Hungary as of 15 August 2026. The case count is 30% above the same point in 2025, which itself ranked as the worst season in a decade. Seven deaths have been confirmed so far this season.

Greece accounts for 89 of those cases, with clusters concentrated in the Thessaloniki basin, Attica, and the Peloponnese. The Cyprus Ministry of Health issued a precautionary advisory this week urging residents and visitors to use insect repellent containing DEET or picaridin at dawn and dusk, wear long sleeves in the evening hours, and eliminate standing water — puddles, plant saucers, and uncovered water storage containers — from homes and gardens.

West Nile virus is spread by Culex mosquitoes that bite infected birds and then humans. About 80% of infected people develop no symptoms; roughly 20% experience a mild fever, headache, and body aches that resolve within a week; fewer than 1% progress to neurological disease including encephalitis or meningitis. Older adults, solid-organ transplant recipients, and people on immunosuppressive medications are at highest risk of the severe form. There is no approved human vaccine and no specific antiviral treatment; supportive care — including mechanical ventilation in intensive care settings for the most severe cases — is the mainstay of management.

Climate scientists tracking Culex population dynamics in the eastern Mediterranean note that warming autumn temperatures are extending the active mosquito season by approximately three weeks compared with the 2010 baseline, broadening the geographic risk zone northward and westward each year.

Monday, 17 August: Neurosteroid Pill Achieves Rapid Remission in Treatment-Resistant Depression

A Phase 3 trial published today in the New England Journal of Medicine found that zuranolone — a synthetic neurosteroid that acts on GABA-A receptors to rapidly recalibrate inhibitory brain signalling — produced full remission in 41% of patients with treatment-resistant major depressive disorder after a 14-day nightly course, compared with 23% on placebo. Response rates diverged from placebo as early as day 3, a speed that is essentially unprecedented among oral antidepressants.

The trial enrolled 482 adults who had failed at least two adequate antidepressant courses at therapeutic doses. Participants took a 50 mg capsule each evening for 14 days; the course can be repeated if depressive symptoms return. The most common adverse effects — dizziness, sleepiness, and headache — were predominantly mild to moderate and resolved after the treatment course ended, without the persistent sexual side effects or discontinuation syndromes associated with long-term SSRI use.

Conventional antidepressants typically require four to six weeks to produce measurable benefit, a waiting period that carries serious risks of deterioration. Zuranolone's mechanism bypasses the slow receptor-upregulation pathway entirely, acting instead on synaptic inhibition in a matter of hours. The US FDA already approved zuranolone at 50 mg for postpartum depression (Zurzuvae) and at 30 mg for standard major depressive disorder; the manufacturer has submitted a supplemental new drug application covering the treatment-resistant indication. An EMA application is expected to follow the Phase 3 data.

Saturday, 16 August: WHO Reports Global Scale-Up of Shorter Tuberculosis Regimen

The World Health Organization announced this weekend that 52 countries have now adopted the BPaLM regimen — bedaquiline, pretomanid, linezolid, and moxifloxacin — as the standard of care for drug-resistant tuberculosis, following its endorsement in WHO's updated clinical guidelines. BPaLM cuts treatment duration from the previous 18–24 months to six months and eliminates injectable agents such as amikacin and kanamycin, which carry significant risks of irreversible hearing loss and kidney injury.

Implementation data reported from 28 of those 52 countries show treatment success rates above 85%, compared with 60–70% for older drug-resistant regimens — a substantial improvement for a disease that killed approximately 1.3 million people in 2025, predominantly in South Asia and sub-Saharan Africa. Cyprus and other EU countries treat relatively few drug-resistant TB cases domestically, but the shorter, all-oral protocol has global significance for the patients most at risk.

Sunday, 16 August: Drug-Resistant Gonorrhoea Cases Rise 32% Across the EU

The ECDC's annual drug-resistance surveillance report, published in Euro Surveillance, documents a 32% increase in extensively drug-resistant Neisseria gonorrhoeae infections across 22 EU/EEA member states in 2025. Greece reported its first confirmed cluster of pan-resistant strains — isolates resistant to every currently licensed antibiotic class — and Cyprus recorded its first confirmed cases of the high-level azithromycin-resistant clone that has been spreading across the eastern Mediterranean since 2024.

The practical implication is narrowing fast. For most cases in Europe, the only reliably effective first-line treatment is now a combined intramuscular injection of ceftriaxone — oral alternatives are falling away as resistance accumulates. The WHO classifies gonorrhoea as a critical-priority antimicrobial-resistance pathogen; a Phase 3 trial of zoliflodacin, a first-in-class spiropyrimidinetrione antibiotic targeting gonorrhoea specifically, is expected to report its primary endpoints before the end of 2026. A positive result would represent the first genuinely new gonorrhoea antibiotic in more than three decades.

This article is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any change to medication, treatment, or health management.